

STATE OF NEW YORK

1890--A

2023-2024 Regular Sessions

IN SENATE

January 17, 2023

Introduced by Sens. SANDERS, ASHBY, CLEARE, COMRIE, GIANARIS, JACKSON, KENNEDY, KRUEGER, MAY, MAYER, MYRIE, PARKER, RAMOS, ROLISON, SEPULVEDA, SKOUFIS, WEBB -- read twice and ordered printed, and when printed to be committed to the Committee on Health -- recommitted to the Committee on Health in accordance with Senate Rule 6, sec. 8 -- reported favorably from said committee and committed to the Committee on Finance -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee

AN ACT to amend the public health law, in relation to establishing the "Syd O. Sotillo Sickle Cell Treatment Act"

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Short title. This act shall be known and may be cited as the "Syd O. Sotillo Sickle Cell Treatment Act".

§ 2. The public health law is amended by adding a new section 2807-bb to read as follows:

§ 2807-bb. Sickle cell centers for excellence and outpatient treatment centers. 1. Centers for sickle cell care excellence. The commissioner shall designate five general hospitals or hospices under article forty of this chapter, upon successful application, as centers for sickle cell care excellence. The designations shall be made through an application designed by the department, and based on service, staffing and other criteria as developed by the commissioner. The centers of excellence shall provide specialized sickle cell disease care, treatment, palliative care, education and related services and shall conduct specialized research into the care, treatment and management of sickle cell disease. Designation as a center for sickle cell care excellence shall not entitle a center to enhanced reimbursement, but may be utilized in outreach and other promotional activities. Each center for sickle cell care excellence shall affiliate and cooperate with major centers of higher learning, including medical colleges, and life science research insti-

EXPLANATION--Matter in italics (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD05963-02-4

1 tutes in the state. The state university shall enter into appropriate
2 legal agreements to enable this cooperation. Each center for sickle cell
3 care excellence shall receive two hundred thousand dollars per year from
4 the department, from amounts appropriated for that purpose, to be used
5 on sickle cell disease research.

6 2. Outpatient treatment centers. The commissioner shall designate ten
7 hospitals, distributed based on sickle cell patient population concen-
8 trations, as sickle cell outpatient treatment centers which shall
9 provide patients treatment for sickle cell disease as an outpatient.
10 Each sickle cell outpatient treatment center shall receive one hundred
11 thousand dollars per year from the department, from amounts appropriated
12 for that purpose, to be used to ensure the proper management and equip-
13 ping of the centers to care for sickle cell patients.

14 § 3. Subdivision 8 of section 3331 of the public health law, as added
15 by section 7-a of part D of chapter 57 of the laws of 2018, is amended
16 to read as follows:

17 8. No opioids shall be prescribed to a patient initiating or being
18 maintained on opioid treatment for pain which has lasted more than three
19 months or past the time of normal tissue healing, unless the medical
20 record contains a written treatment plan that follows generally accepted
21 national professional or governmental guidelines. The requirements of
22 this paragraph shall not apply in the case of patients who are being
23 treated for cancer or sickle cell disease that is not in remission, who
24 are in hospice or other end-of-life care, or whose pain is being treated
25 as part of palliative care practices.

26 § 4. This act shall take effect immediately.